Bioterror Funding Will Aid Development Of "Civilian" Vaccines – Researchers
This article was originally published in The Pink Sheet Daily
Executive Summary
Research conducted with bioterrorism funds will facilitate the development of vaccines for diseases that cannot be used in biological warfare, vaccine researchers Stanley Plotkin and James Nataro say. HIV, malaria and TB continue to be the most significant diseases without a vaccine, the researchers agree.
You may also be interested in...
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.
Senate “BioShield II” Hearing On Incentives Slated Tentatively For Oct. 6
The joint Senate HELP-Judiciary hearing will include representatives from small and large companies and feature discussion on greater funding and stronger liability protections than are included in the existing BioShield law.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter